← NewAmsterdam Pharma Co N.V. (NAMS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
NewAmsterdam Pharma Co N.V. (NAMS)
Pharmaceutical Preparations · market cap $2.7B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
6
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
NewAmsterdam Pharma (NAMS) is a ~$3.9B market-cap lipid-modulation company built around obicetrapib, a CETP inhibitor, with its lead asset being a fixed-dose combination (FDC) of obicetrapib 10 mg + ezetimibe 10 mg in Phase 3 for lipidemia. The company carries $457.6M in cash (~44.9 months runway) and no net debt, with two Phase 3 readouts expected in late 2026 that represent binary catalysts for the thesis.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-11-15 (est.)Phase 3 · Obicetrapibimp 9/10
- 2026-11-15 (est.)Phase 2 · obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeksimp 7/10
- 2026-12-31 (est.)Regulatoryimp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Obicetrapib 5mg | Phase 2 | Dyslipidemias |
| Monotherapy obicetrapib | Phase 3 | Dyslipidemias |
| obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks | Phase 2 | Dyslipidemias |
| Obicetrapib 10mg | Phase 2 | Antioxidant Absorption |
| Obicetrapib | Phase 3 | Dyslipidemias |
| Obicetrapib 10 mg | Phase 3 | Lipidemia |
Price & technical context
3-month
-30.6%
6-month
-26.4%
12-month
-15.0%
52-wk range
$21.16–$41.45
vs 50-day MA
-6.3%
vs 200-day MA
-22.6%
Realized vol
54.9%
Max drawdown
-49.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NAMS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.